Stocks and Investing
Stocks and Investing
Thu, May 4, 2023
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
Dan Brennan Maintained (TXG) at Buy with Increased Target to $66 on, May 4th, 2023
Dan Brennan of TD Cowen, Maintained "10x Genomics, Inc." (TXG) at Buy with Increased Target from $62 to $66 on, May 4th, 2023.
Dan has made no other calls on TXG in the last 4 months.
There are 2 other peers that have a rating on TXG. Out of the 2 peers that are also analyzing TXG, 1 agrees with Dan's Rating of Hold. Following is the relevant analyst calls for the last 4 months
- John Sourbeer of "UBS" Initiated at Hold and Held Target at $50 on, Thursday, February 2nd, 2023
This is the rating of the analyst that currently disagrees with Dan
- Tejas Savant of "Morgan Stanley" Maintained at Buy with Increased Target to $65 on, Thursday, February 16th, 2023
Contributing Sources